4 unchanged sentences
On November 14, 2024 the Company filed a complaint against NowDiagnostics, Inc.
−Removed: ("NowDx"), Jody Berry ("Berry") and Janean Young ("Young") in the United States District Court for the Eastern District of Pennsylvania alleging misappropriation and misuse of the Company's proprietary information and trade secrets by NowDx, Berry and Young in violation of the Federal Defend Trade Secrets Act and the Pennsylvania Uniform Trade Secrets Act.
+Added: ("NowDx"), Jody Berry ("Berry") and Janean Young ("Young") in the United States District Court for the Eastern District of Pennsylvania alleging
+Added: misappropriation and misuse of the Company's proprietary information and trade secrets by NowDx, Berry and Young in violation of the Federal Defend Trade Secrets Act and the Pennsylvania Uniform Trade Secrets Act.
The complaint also alleges breach of contract and duty of loyalty by Young, unfair competition by NowDx, and tortious interference with contractual relations by Berry and NowDx.
1 unchanged sentence
Young filed a Motion to Dismiss the claims against her, which was denied by the court on February 4, 2025.
−Removed: NowDx, Berry, and Young agreed to a preliminary injunction which the Court entered on February 27, 2025.
+Added: NowDx, Berry, and Young agreed to a preliminary injunction which the Court entered on February 27, 2025 and that remains in place.
On February 11, 2026, the Court issued an order scheduling trial for January 17, 2027.
−Removed: The case is currently in the discovery phase.
There have been no material changes to the risk factors disclosed in Item 1A, entitled “Risk Factors,” in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 9, 2026.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.